Oncolytics Biotech submits Type C meeting request to FDA for pelareorep trial in HR+/HER2- metastatic breast cancer.
Biotech innovations are advancing the fight against breast cancer, with companies like Oncolytics Biotech, Gilead Sciences, G1 Therapeutics, AstraZeneca, and Hologic developing new treatments. Oncolytics Biotech recently submitted a Type C meeting request to the FDA, discussing their planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer, with overall survival results expected in H2 2024.
April 11, 2024
5 Articles